Key Takeaway: Syndax reported a strong financial performance for the second quarter of 2026, with total revenues reaching $73 million, marking a 92% increase compared to the previous year. The company's Revuforj® (revumenib) generated net revenues of $54.7 million, while Niktimvo™ (axatilimab-csfr) achieved net revenues of $60.3 million, reflecting significant year-over-year growth.
Price reaction · baseline $19.08 (2026-08-04 close) · hit after-hours · clean, no other SNDX news in the window
day 0 close
+4.4%
day 1
+3.6%
day 3
+6.8%
Market Sentiment Analysis
POSITIVE FACTORS
Total revenue increased by 92% year-over-year.
Revuforj® (revumenib) net revenue rose by 91%.
Niktimvo™ (axatilimab-csfr) net revenue increased by 67%.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+133%
120-day peak, hindsight
Typical move
4.6%
average across 6 past catalysts
Cash runway
~41 mo
Low dilution risk
Lead asset
entinostat
Phase 1 · Epithelial Ovarian Cancer
Full Press Release Details
– Total revenue of $73 million in 2Q26, a 92% year-over-year increase – – Revuforj ® (revumenib) net revenue of $54.7 million in 2Q26, a 91% year-over-year increase – – Niktimvo™ (axatilimab-csfr) net revenue of $60.3 million in 2Q26, a 67% year-over-year increase, resulting in Syndax collaboration
Frequently Asked Questions
What was Syndax's total revenue in Q2 2026?
Syndax reported a total revenue of $73 million in Q2 2026.
How much did Revuforj® earn in Q2 2026?
Revuforj® (revumenib) generated net revenue of $54.7 million.
What was the year-over-year growth for Niktimvo™?
Niktimvo™ (axatilimab-csfr) saw a 67% year-over-year increase in revenue.
What is the significance of Syndax's Q2 2026 results?
The results reflect a strong financial performance with significant revenue growth.